ATyr Pharma (NASDAQ:LIFE) has dosed
the first patient in a Phase 2 study evaluating ATYR1923, in
hospitalized COVID-19 patients with severe respiratory complications who
do not require mechanical ventilation.
The study is expected to enroll 30 patients at up
to 10 centers in U.S. and the company expects to have the majority of
centers enrolling within the coming weeks.
The trial is designed to evaluate the preliminary
safety and efficacy of ATYR1923 as compared to placebo through the
assessment of key clinical outcome measures such as fever and hypoxia as
well as inflammatory biomarkers.
ATYR1923 is an immunomodulator that has been shown
to preclinically downregulate T-cell responses and improve inflammation
and lung function.
https://seekingalpha.com/news/3582954-dosing-underway-in-atyr-pharmas-atyr1923-study-in-covidminus-19-patients
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.